{"product_id":"understanding-trigeminal-neuralgia-how-well-is-it-diagnosed-and-managed-in-uk-general-practice","title":"Understanding Trigeminal Neuralgia: How Well Is It Diagnosed and Managed in UK General Practice?","description":"\u003cp\u003eTrigeminal neuralgia (TN) is a severe, chronic facial pain condition that can devastate quality of life, yet new research from five UK general practices suggests it may be more common than previously believed — affecting approximately 22.3 in 10,000 patients — while also revealing that key diagnostic criteria are frequently not documented and many patients are not referred for specialist care or imaging. Researchers reviewed records from 55,842 patients to identify 157 with facial pain or TN, finding that only 53.6% of TN patients received the gold-standard medication carbamazepine, and fewer than half were referred to secondary care. The study highlights the urgent need for better awareness, decision-support tools, and clear care pathways so that patients can be diagnosed accurately and treated promptly.\u003c\/p\u003e\n\n\u003ch1\u003eUnderstanding Trigeminal Neuralgia: How Well Is It Diagnosed and Managed in UK General Practice?\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eWhat Is Trigeminal Neuralgia?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#why-important\"\u003eWhy This Research Matters\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#study-methods\"\u003eHow the Study Was Conducted\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#key-findings\"\u003eKey Findings: Diagnosis, Medications, and Referrals\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#clinical-implications\"\u003eWhat This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eStudy Limitations\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations and Next Steps\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eA 2023 UK study of 55,842 primary care patients found trigeminal neuralgia prevalence was 22.3 per 10,000, higher than older estimates.\u003c\/li\u003e\n\u003cli\u003eOnly 5.6% of 125 TN patients had all seven ICHD-3 diagnostic criteria documented in GP records.\u003c\/li\u003e\n\u003cli\u003eFewer than half of TN patients were referred to secondary care, limiting access to specialist input and recommended imaging.\u003c\/li\u003e\n\u003cli\u003e28% of TN patients had anxiety or depression, exceeding the national average of 17%, highlighting the need for mental health support.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eWhat Is Trigeminal Neuralgia?\u003c\/h2\u003e\n\u003cp\u003eTrigeminal neuralgia (TN) is a long-term condition that causes sudden, severe facial pain, usually on one side of the face. The pain is often described as \u003cstrong\u003eabrupt, short-lasting, stabbing, and recurrent\u003c\/strong\u003e, and it occurs in areas served by the trigeminal nerve — the nerve responsible for sensation in the face. TN is sometimes called the \"suicide disease\" because of the excruciating nature of the pain and its profound impact on mental health.\u003c\/p\u003e\n\u003cp\u003eThe condition takes a heavy toll on sufferers' quality of life and emotional wellbeing. Recent UK data has shown that poorly managed TN can lead to \u003cstrong\u003esocial isolation, depression, loss of employment, and relationship breakdowns\u003c\/strong\u003e. Studies in the United States have also found that patients with TN are at higher risk of suicide than the general population. A population-based study in Taiwan similarly highlighted increased risks of depression, anxiety, and sleep disorders after a TN diagnosis.\u003c\/p\u003e\n\u003cp\u003eTN is generally considered a rare disease. A US study estimated the prevalence at \u003cstrong\u003e4.1 per 10,000 people\u003c\/strong\u003e. However, more recent studies from the UK and Holland, using primary care records, suggested a higher incidence of \u003cstrong\u003e8 to 12.6 per 100,000 people per year\u003c\/strong\u003e. TN is also linked to multiple sclerosis (MS) in about \u003cstrong\u003e5% to 10% of cases\u003c\/strong\u003e, and there are approximately 110,000 people with MS in the UK. Tumours account for a very small number of TN cases, and there are also reports of familial (genetic) links.\u003c\/p\u003e\n\n\u003ch2 id=\"why-important\"\u003eWhy This Research Matters\u003c\/h2\u003e\n\u003cp\u003ePatients with facial pain almost always first visit their general practitioner (GP). Yet until now, there has been surprisingly little research into whether GPs are diagnosing and managing TN according to current guidelines. This study — published in the \u003cem\u003eBritish Journal of Pain\u003c\/em\u003e in 2023 — set out to answer two important questions:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHow common is trigeminal neuralgia\u003c\/strong\u003e in UK primary care?\u003c\/li\u003e\n  \u003cli\u003eAre primary care clinicians \u003cstrong\u003efollowing official guidelines\u003c\/strong\u003e for diagnosing and managing the condition?\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003eCurrent guidance comes from two key sources. The \u003cstrong\u003eInternational Classification of Headache Disorders, 3rd edition (ICHD-3)\u003c\/strong\u003e defines the diagnostic criteria for TN. The \u003cstrong\u003eNational Institute for Health and Care Excellence (NICE)\u003c\/strong\u003e Neuropathic Pain Guideline 173 recommends that patients be referred to specialist centres if carbamazepine — the gold-standard medication — is not tolerated, is contraindicated, or is ineffective, and if the pain is severe or limiting daily activities. Newer national guidelines also recommend that \u003cstrong\u003eall patients with TN undergo imaging\u003c\/strong\u003e (such as MRI) to rule out secondary causes like MS or tumours.\u003c\/p\u003e\n\n\u003ch2 id=\"study-methods\"\u003eHow the Study Was Conducted\u003c\/h2\u003e\n\u003cp\u003eThis multi-centre case study was carried out across \u003cstrong\u003efive GP practices in the UK during 2019–2020\u003c\/strong\u003e, covering a total patient population of \u003cstrong\u003e55,842 people\u003c\/strong\u003e. The practices had 37 full-time GPs and 10 employed nurses between them. Patient records dating from 1970 to 2020 were reviewed.\u003c\/p\u003e\n\u003cp\u003eThe researchers used two primary care record systems — \u003cstrong\u003eEMIS\u003c\/strong\u003e and \u003cstrong\u003eSystmOne\u003c\/strong\u003e — to search for patients coded with trigeminal neuralgia (TN) or facial pain (FP). They searched for codes including \"trigeminal nerve disorder,\" \"trigeminal neuralgia,\" and \"atypical facial pain.\" Initial results identified \u003cstrong\u003e218 patients\u003c\/strong\u003e; after excluding 61 who didn't meet the criteria, the final study group included \u003cstrong\u003e157 patients\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eThese 157 patients were divided into two groups:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFP group (n = 54):\u003c\/strong\u003e Patients with facial pain, including codes for \"pain in face,\" \"facial pain,\" and \"atypical facial pain.\"\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTN group (n = 103):\u003c\/strong\u003e Patients with diagnosed TN, including codes for \"trigeminal neuralgia NOS\" (not otherwise specified), \"trigeminal nerve disorders,\" and \"decompression of trigeminal nerve.\"\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eAfter a detailed review of patient records, \u003cstrong\u003e125 patients had a final diagnosis of TN\u003c\/strong\u003e. This number included 102 patients originally coded with TN, 17 patients initially coded with facial pain, and 6 patients who had no initial code.\u003c\/p\u003e\n\n\u003cp\u003eThe demographics of the two groups differed somewhat. In the FP group (n = 54), ages ranged from 34 to 86 years with a median age of 61.5; there were 12 males and 42 females. In the TN group (n = 102 initially), ages ranged from 20 to 91 with a median age of 58; there were 26 males and 76 females. The final TN group of 125 patients included \u003cstrong\u003e95 women and 30 men\u003c\/strong\u003e, confirming that TN affects women more often than men.\u003c\/p\u003e\n\n\u003ch2 id=\"key-findings\"\u003eKey Findings: Diagnosis, Medications, and Referrals\u003c\/h2\u003e\n\n\u003ch3\u003ePrevalence: Higher Than Previously Thought\u003c\/h3\u003e\n\u003cp\u003eThis study found a TN prevalence of \u003cstrong\u003e0.223%, or 22.3 per 10,000 people\u003c\/strong\u003e. This is significantly higher than the older US estimate of 4.1 per 10,000. The prevalence varied considerably between practices, from \u003cstrong\u003e0.086%\u003c\/strong\u003e at Practice 3 (12,803 patients) and \u003cstrong\u003e0.098%\u003c\/strong\u003e at Practice 1 (11,209 patients) to a striking \u003cstrong\u003e0.364%\u003c\/strong\u003e at Practice 5 (17,026 patients). Practice 2 (3,712 patients) had a prevalence of 0.108%, and Practice 4 (11,092 patients) had 0.130%.\u003c\/p\u003e\n\u003cp\u003eThe authors note that this higher prevalence means it is \u003cstrong\u003e\"likely that all GPs will encounter such a patient\"\u003c\/strong\u003e in their career — making it essential that GPs know how to recognise and treat the condition.\u003c\/p\u003e\n\n\u003ch3\u003eIncomplete Documentation of Diagnostic Criteria\u003c\/h3\u003e\n\u003cp\u003eThe ICHD-3 criteria for TN require documentation of \u003cstrong\u003eseven key features\u003c\/strong\u003e to confirm a positive diagnosis. These include the laterality (one-sided nature) of the pain, its distribution along trigeminal nerve branches, the quality or character of the pain (e.g., electric shock-like, shooting, stabbing), its intensity (severe), its duration (typically under 2 minutes), whether it occurs in episodic attacks, and the presence of trigger factors.\u003c\/p\u003e\n\u003cp\u003eThe results were striking — and concerning. Of the \u003cstrong\u003e125 patients diagnosed with TN\u003c\/strong\u003e:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eOnly \u003cstrong\u003e7 patients (5.6%)\u003c\/strong\u003e had all seven ICHD-3 criteria documented in their records.\u003c\/li\u003e\n  \u003cli\u003eOnly \u003cstrong\u003e2 patients (1.6%)\u003c\/strong\u003e were positive for all seven symptoms.\u003c\/li\u003e\n  \u003cli\u003eThe \u003cstrong\u003eaverage number of symptoms recorded per patient was just 3.7\u003c\/strong\u003e, despite seven being required for a positive diagnosis according to ICHD-3.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eLooking at individual symptoms among the 125 TN patients:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLaterality\u003c\/strong\u003e was the most consistently recorded symptom (88.0% of patients), and of those, 97.3% had unilateral (one-sided) pain, which matches TN.\u003c\/li\u003e\n  \u003cli\u003eOnly \u003cstrong\u003e46.4%\u003c\/strong\u003e of records documented whether the pain was episodic or continuous; of those, 89.7% reported episodic pain, consistent with TN.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSeverity\u003c\/strong\u003e was recorded in only \u003cstrong\u003e24.8%\u003c\/strong\u003e of patients, though 74.2% of those recorded reported severe pain — again matching the ICHD-3 criteria.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe researchers also compared symptom documentation between the FP and TN groups. Unilateral symptoms were recorded in 91.1% of FP patients versus 98.9% in the TN group. However, only 26.7% of FP patients had pain in a trigeminal nerve distribution, compared with 43.5% in the TN cohort. Both groups mostly reported episodic pain (91.7% for FP, 88.1% for TN).\u003c\/p\u003e\n\u003cp\u003eDuration of pain was \u003cstrong\u003erarely recorded in either group (less than 20%)\u003c\/strong\u003e. In the FP group, 30.0% reported pain lasting less than 2 minutes, versus 47.1% in the TN group. Pain character was recorded in 42.6% of FP patients and 53.9% of TN patients. Neuropathic-type descriptors that do \u003cem\u003enot\u003c\/em\u003e fit ICHD-3 TN criteria (such as \"burning,\" \"tingling,\" and \"numbness\") were documented in 21.7% of the FP group and 18.2% of the TN group. Other pain descriptors, including \"ache,\" \"light brushing sensation,\" and \"pressure,\" were also noted. A trigger factor was recorded in 33.3% of FP patients but only 15.8% of TN patients.\u003c\/p\u003e\n\n\u003ch3\u003eMedication: Gold-Standard Treatment Underused\u003c\/h3\u003e\n\u003cp\u003eCarbamazepine is the current gold-standard first-line medication for TN, as recommended by NICE. The study found a large gap between the two groups in prescribing practices:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e58.8%\u003c\/strong\u003e of patients coded with TN received carbamazepine, compared to just \u003cstrong\u003e16.7%\u003c\/strong\u003e of the FP group.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e38.9%\u003c\/strong\u003e of the FP group were prescribed other neuropathic pain medications (such as amitriptyline or gabapentin), versus \u003cstrong\u003e23.5%\u003c\/strong\u003e in the TN group.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eLooking specifically at the 125 patients with a final diagnosis of TN:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e53.6%\u003c\/strong\u003e were prescribed carbamazepine.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e24.0%\u003c\/strong\u003e were prescribed other neuropathic pain medications (amitriptyline, gabapentin).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e10.4%\u003c\/strong\u003e were prescribed \"other\" medications, including cyclizine, immediate-release oral morphine, sumatriptan, and co-codamol.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e12.0% received no medication at all\u003c\/strong\u003e at the time of initial diagnosis.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe researchers suggest the limited use of carbamazepine may reflect GPs' unfamiliarity with the drug, which is rarely used for other conditions. Since TN is a neuropathic pain condition, they suggest it would be reasonable to consider amitriptyline (if no contraindications) as a first-line option before a formal diagnosis is confirmed.\u003c\/p\u003e\n\n\u003ch3\u003eReferrals to Specialist Care\u003c\/h3\u003e\n\u003cp\u003eReferral patterns also revealed gaps in care. Among TN patients:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e57 patients (47.4%)\u003c\/strong\u003e were referred to secondary care, but only \u003cstrong\u003e33\u003c\/strong\u003e had a specialist letter available in their records.\u003c\/li\u003e\n  \u003cli\u003eThe most common referral destination was \u003cstrong\u003eneurology (47.4%)\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003eOther referrals included dentists (\u003cstrong\u003e12.3%\u003c\/strong\u003e), maxillo-facial specialists (\u003cstrong\u003e12.3%\u003c\/strong\u003e), ear, nose, and throat (ENT) services (\u003cstrong\u003e10.5%\u003c\/strong\u003e), and specialty pain clinics (\u003cstrong\u003e8.8%\u003c\/strong\u003e).\u003c\/li\u003e\n  \u003cli\u003eFive patients required a \u003cstrong\u003esecond referral\u003c\/strong\u003e: three to neurology, one to ENT, and one to a pain clinic.\u003c\/li\u003e\n  \u003cli\u003eIn 19 cases, referrals were made in the same year as the initial GP consultation.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eIn contrast, \u003cstrong\u003e66.7%\u003c\/strong\u003e of patients in the FP group were referred to secondary care, compared with only \u003cstrong\u003e38.2%\u003c\/strong\u003e of those coded with TN. This suggests that patients with TN may actually be \u003cem\u003eless\u003c\/em\u003e likely to receive specialist input than patients with more general facial pain.\u003c\/p\u003e\n\u003cp\u003eNone of the patients in this cohort received surgical treatment for their TN. It's unclear whether this was because medical management was adequate, patients preferred not to have surgery, or surgery was deemed unsuitable.\u003c\/p\u003e\n\n\u003ch3\u003eThe Diagnostic Journey: Delays and Coding Changes\u003c\/h3\u003e\n\u003cp\u003eTwenty-two patients with a final diagnosis of TN were not initially coded with TN: five had no initial code, and 17 were initially coded as having facial pain. For 17 of these patients, their coding changed following a referral — five to neurology, three to ENT, three to pain clinic, three to maxillo-facial services, one to neurosurgery, one to A\u0026amp;E, and one to a dentist. The remaining five patients had their coding changed without any documented referral, and the reasons remain unclear.\u003c\/p\u003e\n\u003cp\u003eThis fragmented diagnostic journey is concerning. Data from a London specialist centre shows the \u003cstrong\u003emean delay in referral to secondary care can be between 4 and 7 years\u003c\/strong\u003e, and this can be significantly extended further in patients who receive multiple referrals to different specialities. GPs tend to refer to general neurologists, whereas dental surgeons refer to oral and maxillo-facial surgical teams, leading to further delays.\u003c\/p\u003e\n\n\u003ch3\u003eMental Health and Comorbidities\u003c\/h3\u003e\n\u003cp\u003eThe study found that \u003cstrong\u003e28.0% of TN patients had a concurrent diagnosis of anxiety or depression\u003c\/strong\u003e. This is notably higher than the national incidence of \u003cstrong\u003e17%\u003c\/strong\u003e in England (based on the 2014 Adult Psychiatric Morbidity Survey), emphasising the profound impact of TN on patients' mental health and quality of life. These patients with anxiety or depression made up 12.3% of all patients referred to secondary care.\u003c\/p\u003e\n\u003cp\u003eInterestingly, \u003cstrong\u003eno patients in either group had a concurrent diagnosis of multiple sclerosis\u003c\/strong\u003e. The authors note that the prevalence of TN in MS patients has previously been reported at approximately 4%, and TN can be the presenting symptom in 11% of MS patients.\u003c\/p\u003e\n\n\u003ch2 id=\"clinical-implications\"\u003eWhat This Means for Patients\u003c\/h2\u003e\n\u003cp\u003eThis study carries several important messages for patients living with — or suspected of having — trigeminal neuralgia.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eFirst, you are not alone.\u003c\/strong\u003e The prevalence of 22.3 per 10,000 people is higher than older estimates suggested, meaning TN affects more people in the UK than previously recognised.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSecond, diagnosis can be incomplete.\u003c\/strong\u003e The fact that so few patients had all seven ICHD-3 diagnostic criteria documented suggests that some patients may be misdiagnosed or experience delays before receiving the correct diagnosis. If your GP has not asked about all the key features of your pain — whether it's one-sided, sudden, short-lasting, stabbing, severe, and triggered by specific activities — you may want to proactively describe these details yourself.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eThird, treatment options may be underused.\u003c\/strong\u003e Carbamazepine remains the first-line medication and can be highly effective for many patients. If you have not been offered carbamazepine, or if it hasn't worked for you, ask your GP about alternatives such as amitriptyline or gabapentin, and whether a referral to a specialist pain clinic or neurologist could help.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eFourth, imaging matters.\u003c\/strong\u003e New national guidelines recommend that \u003cem\u003eall\u003c\/em\u003e patients with TN undergo imaging (such as MRI) to rule out secondary causes like MS or tumours. Since fewer than half of TN patients in this study were referred to secondary care, many may be missing out on this important step.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eFifth, mental health support is essential.\u003c\/strong\u003e With 28% of TN patients also experiencing anxiety or depression — well above the national average of 17% — it's vital to seek help for the emotional toll of living with chronic pain, not just the physical symptoms.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eStudy Limitations\u003c\/h2\u003e\n\u003cp\u003eAs with any research, this study has limitations that should be considered when interpreting the results.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSample size and statistical power:\u003c\/strong\u003e The sample sizes were too small to complete a full statistical analysis looking for significant differences between the FP and TN groups, particularly in determining the causes of misdiagnosis.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePrevalence estimate:\u003c\/strong\u003e The prevalence data was not adjusted for factors such as patients moving between practices, and the exact dates from which records began were not determined.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePotential selection bias:\u003c\/strong\u003e The practices were chosen based on the placements of a group of medical students and doctors interested in trigeminal neuralgia, which could introduce bias. However, the students were randomly allocated to their practices by their medical school or training trust. Importantly, \u003cstrong\u003efour of the five practices were in London\u003c\/strong\u003e, so the findings might not fully represent the whole of the UK.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eReliance on documentation:\u003c\/strong\u003e The study relied heavily on clinical documentation, which was often limited. It's unclear whether the lack of documentation was due to time pressures during consultations or a lack of awareness of diagnostic criteria among GPs. Some consultations were also missing entirely because patients had moved practices and their notes were not transferred.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eVariability between practitioners:\u003c\/strong\u003e The study did not determine which practitioner reviewed each patient, and there may be differences in history-taking, diagnosis, and management plans depending on the experience of the doctor.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eTwo record systems:\u003c\/strong\u003e The use of two different primary care record systems (EMIS and SystmOne) may have introduced differences in the way codes were applied. Not all letters from secondary care could be identified, making it difficult to verify specialist diagnoses.\u003c\/p\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations and Next Steps\u003c\/h2\u003e\n\u003cp\u003eThe authors offer several concrete recommendations to improve TN care in primary care settings:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eUse condition-specific templates.\u003c\/strong\u003e Standardised templates would help GPs consistently document the seven ICHD-3 criteria and improve diagnostic accuracy.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDevelop a decision-support tool\u003c\/strong\u003e for all patients presenting with acute facial pain in primary care. This could help improve diagnosis and allow care to be initiated earlier.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRefer all TN patients for imaging.\u003c\/strong\u003e Although rare, secondary causes of TN such as MS and acoustic neuromas must be excluded. National guidelines recommend imaging for all TN patients, and this should empower GPs to make non-urgent referrals for all TN patients to ensure an accurate diagnosis.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eEstablish local care pathways\u003c\/strong\u003e so that patients can be referred to secondary care more efficiently and to the correct service. Collaboration with dental surgeons may be appropriate before medical management, as dental pain is very common and can present with similar symptoms.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDisseminate national guidelines\u003c\/strong\u003e through journals read by GPs and on the Royal College of General Practitioners website, so that every GP is aware of current recommendations.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eConduct further epidemiological research\u003c\/strong\u003e using Clinical Practice Research Databases (CPRD) to confirm the true prevalence of TN, its co-morbidities, and how it is managed across the UK.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003ePatients can play an active role too. In a recent TN focus group study, patients themselves highlighted the need for \u003cstrong\u003efaster referral to specialist centres\u003c\/strong\u003e. If you or a loved one experiences sudden, severe, one-sided facial pain, keep a diary of your symptoms — including their quality (stabbing, electric shock-like), duration, triggers, and severity — and take this information to your GP appointment. It can make a real difference in getting an accurate diagnosis sooner.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is trigeminal neuralgia and what does the pain feel like?\u003c\/h3\u003e\n\u003cp\u003eTrigeminal neuralgia is a long-term condition causing sudden, severe facial pain, usually on one side, in the area served by the trigeminal nerve. The pain is often described as abrupt, short-lasting, stabbing, and recurrent. It can severely impact quality of life and emotional wellbeing, sometimes leading to depression, social isolation, or loss of employment.\u003c\/p\u003e\n\u003ch3\u003eHow common is trigeminal neuralgia in the UK?\u003c\/h3\u003e\n\u003cp\u003eA 2023 UK study across five general practices found a prevalence of 22.3 per 10,000 people, which is higher than older US estimates of 4.1 per 10,000. The study suggests that most GPs will encounter at least one patient with trigeminal neuralgia during their career, so awareness and accurate diagnosis are important.\u003c\/p\u003e\n\u003ch3\u003eWhat diagnostic criteria do doctors use for trigeminal neuralgia?\u003c\/h3\u003e\n\u003cp\u003eThe ICHD-3 criteria list seven key features: one-sided pain, distribution along trigeminal nerve branches, electric shock-like or stabbing character, severe intensity, episodes lasting under 2 minutes, occurring in attacks, and triggered by specific factors. In a 2023 study, only 5.6% of patients had all seven documented in their GP records.\u003c\/p\u003e\n\u003ch3\u003eShould I have an MRI scan if I have trigeminal neuralgia?\u003c\/h3\u003e\n\u003cp\u003eNewer national guidelines recommend that all patients with trigeminal neuralgia undergo imaging, such as MRI, to rule out secondary causes like multiple sclerosis or tumours. However, the 2023 study found that fewer than half of TN patients were referred to secondary care, so many may miss this important step.\u003c\/p\u003e\n\u003ch3\u003eHow does trigeminal neuralgia affect mental health?\u003c\/h3\u003e\n\u003cp\u003eThe 2023 study found that 28% of trigeminal neuralgia patients also had anxiety or depression, higher than the national average of 17%. The condition's severe pain can lead to social isolation, relationship breakdowns, and even higher suicide risk, so seeking mental health support is essential alongside physical treatment.\u003c\/p\u003e\n\u003ch3\u003eWhat should I do if I think I have trigeminal neuralgia?\u003c\/h3\u003e\n\u003cp\u003eKeep a diary of your symptoms, including pain quality (e.g., stabbing, electric shock-like), duration, triggers, and severity. Bring this to your GP appointment. Consider asking about the seven ICHD-3 diagnostic criteria, discuss carbamazepine or other neuropathic pain medications, and ask whether a referral to a specialist or MRI is appropriate.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eOriginal Article:\u003c\/strong\u003e \"Management of trigeminal neuralgia: A multi-centre case study in general practice\"\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Zofia J Zakrzewska, Parinaz Hosseini-Ashrafi, Ishrat Hussain, Zachary James Moulder, Jithu Subhash, Melissa Tan, Martin Ewart Johnson, and Joanna M Zakrzewska\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eJournal:\u003c\/strong\u003e British Journal of Pain, 2023, Vol. 17(6), pages 606–612\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOI:\u003c\/strong\u003e 10.1177\/20494637231199332\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding:\u003c\/strong\u003e The authors received no financial support for the research, authorship, and\/or publication of this article.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eConflicts of Interest:\u003c\/strong\u003e The authors declared no potential conflicts of interest.\u003c\/p\u003e\n\u003cp\u003e\u003cem\u003eThis patient-friendly article is based on peer-reviewed research. It is intended for educational purposes and does not constitute medical advice. Always consult a qualified healthcare professional regarding any medical condition or treatment decisions.\u003c\/em\u003e\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47427815342236,"sku":null,"price":0.0,"currency_code":"EUR","in_stock":true}],"url":"https:\/\/diagnosticdetectives.fi\/products\/understanding-trigeminal-neuralgia-how-well-is-it-diagnosed-and-managed-in-uk-general-practice","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}